alkylating agents: cross links DNA
	- cyclophosphamide: hemorrhagic cystitis + AML/MDS + fertility
	- ifosfamide: cyclo effects + CNS/renal toxicity

platinums: cross links DNA
	- cisplatin: neuro/otoxicity + nephrotoxicity (hydrate)
	- carboplatin: neuropathy
	- oxaliplatin: cold neuropathy

antimetabolites:
	- 5-fluorouracil (5FU) / capecitabine (oral): DPD deficiency -> fatal
	- methotrexate: S phase + renal toxicity (alkalize urine) + rescue w/ leucovorin
	- gemcitabine: TTP

anti-microtubules:
	- taxanes: paclitaxel / docetaxel: G2 phase + peripheral neuropathy
	- vincristine: M+S phase + constipation/ileus + peripheral neuropathy

topoisomerase I inhibitors:
	- irinotecan
	- topotecan

topoisomerase II inhibitors: complexes DNA + topoII
	- etoposide: AML/MDS

anthracyclines: intercalates DNA + topoIIi + free radicals
	- doxorubicin: cardiomyopathy + AML/MDS

anti-tumor antibiotics: DNA breaks
	- bleomycin: pneumonitis + pulmonary fibrosis



HER2+ targeted:
	- trastuzumab: reversible cardiomyopathy
	- pertuzumab: reversible cardiomyopathy

EGFR/EGF targeted:
	- cetuximab: acneiform rash

VEGF targeted:
	- bevacizumab: htn, bleeding/clotting, poor wound healing, GI perforation, fistulas, nephrotic syndrome

HER2 targeted:
	- Ado-trastuzumab emtansine (T-DM1): microtubule-i + neuropathy + reversible cardiomyopathy
	- fam-trastuzumab deruxtecan (T-Dxd): topoIi + ILD/pneumonitis + reversible cardiomyopathy

Trop-2 targeted:
	- sacituzimab govitecan: topoIi + elevated AST/ALT



checkpoint inhibitors:
	- pembrolizumab / nivolumab (PD-1)
	- atezolizumab (PD-1L)
	- ipilimumab (CTLA-4)



selective estrogen receptor modulator (SERM):
	- tamoxifen: G0 + G1 phase + TE + hot flashes + endometrial cancer + improved bone health

aromatase inhibitors:
	- anastrazole, letrozole, exemestane: arthralgias + hot flashes + decreased bone density

GnRH agonists:
	- leuprolide, goserelin: ED + osteoporosis + hot flashes + vasomotor sx + cardiovascular disease

anti-androgen:
	- bicalutamide: ED + osteoporosis + hot flashes
	- enzulatamide: fatigue + htn + rare seizures

androgen synthesis inhibitors:
	- abiraterone: mineralocorticoid excess - htn, hyper Na+, hypoK+ - give w/ steroid



CDK 4/6 kinase inhibitors:
	- ribociclib, palbociclib, abemaciclib: G1-S phase + uncomplicated neutropenia + rare pneumonitis

EGFR tyrosine kinase inhibitors: "tinib" if exclude else
	- erlotinib, gefitinib, afatinib, osimertinib: rash - indicates response

ALK + RET tyrosine kinase inhibitors: "al-kt inib"
	- alectinib: myalgia + elevated liver labs

BRAF kinase inhibitors: "rafinib"
	- debrafinib, vemurafinib: basal/squamous cell carcinoma w/o MEKi

MEK kinase inhibitors: "metinib"
	- tremetinib, cobimetinib: retinopathy + skin toxicity 

Bcr-Abl + cKIT tyrosine kinase inhibitors:
	- imatinib: edema

poly ADP-ribose polymerase inhibitors (PARPi): "par -ib"
	- olaparib: DS DNA breaks + AML/MDS

multiple receptor tyrosine kinase inhibitors: "suni + pazo"
	- sunitinib: htn + hand-foot syndrome
	- pazopanib: htn + hand-foot syndrome


therapeutic cancer vaccines:
	- sipuleucel-T: infusion reaction

radiopharmaceutical:
	- radium 223: minor myelosuppresion


osteoclast inhibitors: osteonecrosis + hypocalcemia
	- bisphosphonates (zoledronic acid): renal insufficiency
	- denosumab: 




antibody notes:

u: human
o: mouse
xi: chimeric
zu: humanized

c: C-ardiovascular
l: immunomodu-L-ating
k: interleu-K-in
o (s): b-O-ne
t (u): T-umor
v: V-iral